Boston Scientific Corporation $BSX Stock Holdings Decreased by Machina Capital S.A.S.

Machina Capital S.A.S. trimmed its stake in shares of Boston Scientific Corporation (NYSE:BSX – Free Report) by 47.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 40,951 shares of the medical equipment provider’s stock after selling 36,978 shares during the quarter. Machina Capital S.A.S.’s holdings in Boston Scientific were worth $1,788,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also made changes to their positions in BSX. Silver Grove Financial Group Inc. increased its position in Boston Scientific by 13.5% in the third quarter. Silver Grove Financial Group Inc. now owns 3,190 shares of the medical equipment provider’s stock worth $139,000 after buying an additional 379 shares during the period. Turn8 Private Wealth Inc. lifted its stake in Boston Scientific by 25.5% in the third quarter. Turn8 Private Wealth Inc. now owns 71,026 shares of the medical equipment provider’s stock valued at $3,100,000 after buying an additional 14,421 shares during the last quarter. Knights of Columbus Asset Advisors LLC acquired a new position in shares of Boston Scientific during the third quarter valued at $4,634,000. AMG National Trust Bank acquired a new position in shares of Boston Scientific during the third quarter valued at $1,497,000. Finally, Moneco Advisors LLC bought a new position in shares of Boston Scientific during the third quarter worth about $222,000. Institutional investors own 89.07% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. cut shares of Boston Scientific from an “overweight” rating to a “neutral” rating and set a $46.00 price objective on the stock. in a report on Wednesday, October 28th. BTIG Research cut their price objective on shares of Boston Scientific from $56.00 to $49.00 and set a “buy” rating on the stock in a research report on Thursday, October 29th. Needham & Company LLC reduced their target price on shares of Boston Scientific from $57.00 to $48.00 and set a “buy” rating for the company in a research note on Wednesday, October 28th. Oppenheimer cut shares of Boston Scientific from an “outperform” rating to a “market perform” rating in a research report on Thursday, October 29th. Finally, Canaccord Genuity Group cut their price target on Boston Scientific from $66.00 to $48.00 and set a “buy” rating on the stock in a report on Thursday, October 29th. One research analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.43.

Read Our Latest Research Report on BSX

Boston Scientific Stock Down 2.0%

BSX stock opened at $44.22 on Friday. Boston Scientific Corporation has a 52 week low of $39.57 and a 52 week high of $105.65. The company has a market capitalization of $64.10 billion, a price-to-earnings ratio of 18.74, a price-to-earnings-growth ratio of 1.34 and a beta of 0.60. The firm’s 50-day moving average is $44.05 and its two-hundred day moving average is $54.75. The company has a current ratio of 1.36, a quick ratio of 0.81 and a debt-to-equity ratio of 0.42.

Boston Scientific (NYSE:BSX – Get Free Report) last issued its quarterly earnings results on Wednesday, October 28th. The medical equipment provider reported $0.73 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.73. The company had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Boston Scientific had a net margin of 16.62% and a return on equity of 18.61%. The business’s revenue for the quarter was up 1.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.75 EPS. On average, analysts forecast that Boston Scientific Corporation will post 3.17 earnings per share for the current fiscal year.

Boston Scientific Company Profile

(Free Report)

Boston Scientific is a medical technology company that develops, manufactures and markets devices used in minimally invasive procedures across a range of medical specialties. Founded in 1979, the company is headquartered in Marlborough, Massachusetts. Its products support areas including cardiovascular care, endoscopy, urology and neuromodulation. They include catheter-based devices and therapies for conditions affecting the heart and blood vessels, as well as devices used in diagnostic and therapeutic procedures involving the digestive and urinary systems.

Read More

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX – Free Report).

Institutional Ownership by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.